P1NP and β-CTX: What Bone Turnover Markers Can Tell Us Before a Fracture Happens

In my previous article, I explained why DXA is essential but not continuous. Today, I want to introduce two biological signals that may help us understand what is happening between DXA scans: P1NP and β-CTX.

The Biology of Bone Remodeling

Bone is constantly remodeled; old bone is broken down by osteoclasts, and new bone is formed by osteoblasts. Bone Turnover Markers (BTMs) give us a window into this activity.

- P1NP (Procollagen Type 1 N-Terminal Propeptide): This marker reflects bone formation. It provides information about how actively the body is building new bone matrix.

- β-CTX-I (C-Terminal Telopeptide): This marker reflects bone resorption. It provides information about how actively bone is being broken down.

"The key point is simple: DXA shows bone density. P1NP and β-CTX help show bone activity."  

Figure. Dynamic Bone Turnover Markers: P1NP and CTX vs DXA Snapshot

(Key Terms: P1NP, β-CTX, Osteoporosis Management)

A New Reference for Management

In 2025, international experts from the IOF, ESCEO, and IFCC reaffirmed serum P1NP and plasma β-CTX-I as reference bone turnover markers for osteoporosis management. These markers are especially useful for monitoring treatment response and medication adherence.

The key point is simple: DXA shows bone density, while P1NP and β-CTX show bone activity. They do not replace DXA, nor do they diagnose osteoporosis by themselves. However, they add biological context that DXA alone cannot provide.

Closing the Monitoring Gap

For example, after a patient starts osteoporosis medication, changes in bone turnover markers may appear much earlier than changes on a DXA scan. This allows clinicians to ask better questions:

- Is bone resorption decreasing as expected?
- Is bone formation responding to the therapy?
- Is the patient taking the treatment consistently?

Precision and Standardization

Standardization is critical for accuracy. β-CTX levels can be affected by food intake and time of day, which is why morning fasting collection is strongly recommended. For effective tracking, serial measurements should ideally use the same assay and laboratory.

This is where the future of healthcare is heading: not relying on one scan alone, but building a complete model that combines bone density, biological markers, treatment history, and longitudinal data. This is the beginning of what we call Bone Intelligence.

---------------------------------------------------------------------------------------------------------------------
[Exclusive Access] Request the 2025 Bone Health Intelligence Report
MARA Nanotech has prepared a strategic report on the future of osteoporosis monitoring, integrating the latest global consensus on DXA, bone turnover markers, and precision bone health management with MARA’s Digital ELISA and quantitative POCT technology roadmap.


[Request Access to the Technology Whitepaper & Global Report]
This report is intended for pharmaceutical partners, diagnostic laboratories, women’s health organizations, and investors interested in the future of Bone Intelligence.

For partnership, investor, or technical inquiries, please contact the MARA Nanotech team at info@maranano.com.

---------------------------------------------------------------------------------------------------------------------

References
1. International Osteoporosis Foundation. Joint consensus highlights the role of bone turnover markers in osteoporosis diagnosis and management. 2025.
2. Mayo Clinic Laboratories. Laboratory Testing of Bone Turnover Markers. 2023.
3. Bhattoa HP, et al. Update on the role of bone turnover markers in the diagnosis and management of osteoporosis. Osteoporosis International. 2025.

[MARA Global Insight] 

"MARA Nanotech’s Global Health Reports are being updated sequentially on our official English blog (health.maranano.com). Be the first to explore the integration of global medical trends and cutting-edge nanotechnology."

[Visit MARA Official Site: https://www.maranano.com/]

About the Author: Dr. HeaYeon Lee is a nanobiosensor scientist and CEO of MARA Nanotech, dedicated to digitizing biological signals for precision health monitoring.

Medical Disclaimer: This article is for educational purposes only and is not intended as medical advice. Patients should consult a qualified healthcare professional before making decisions about osteoporosis screening, diagnosis, or treatment.

Note: Some conceptual images in this article were generated using AI to represent scientific concepts.